Saturday 17 October 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
In the quarter to June 2026, EPS grew 58.7% and free cash flow fell 24.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.33
0.06
−1.37%
Follow CING
Cingulate Inc. (CING) P/E ratio
Cingulate Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HYFT MindWalk Holdings Corp. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)